ProKidney Corp. (PROK)
| Market Cap | 1.92B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -37.20M |
| Shares Out | 419.40M |
| EPS (ttm) | -0.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 283,142 |
| Open | 4.76 |
| Previous Close | 4.71 |
| Day's Range | 4.36 - 4.80 |
| 52-Week Range | 3.95 - 14.19 |
| Beta | 0.67 |
| Analysts | Strong Buy |
| Price Target | 15.60 (+240.61%) |
| Earnings Date | Nov 13, 2023 |
About PROK
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered i... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for PROK stock is "Strong Buy." The 12-month stock price forecast is $15.6, which is an increase of 240.61% from the latest price.
News
Short squeeze alert for September 27th: 2 stocks that could skyrocket
Stock market investors are regularly monitoring highly shorted stocks, as the potential for an abrupt surge looms large.
ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference
WINSTON-SALEM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving...
Short squeeze alert for September 4th: Two stocks with potential to skyrocket
A short squeeze is when traders who heavily short a stock start to cover their short positions by buying back the stock. This increases demand for the stock, and it pushes the price higher, forcing ot...
ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights
WINSTON-SALEM, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on dialysis-fr...
ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC
WINSTON-SALEM, N.C., July 18, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving ...
ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization
- Brings more than 20 years of academic and industry experience with extensive expertise in kidney disease - WINSTON-SALEM, N.C., July 17, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“Pr...
ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC
WINSTON-SALEM, N.C., June 13, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving ...
ProKidney to Participate in Fireside Chat at the Jefferies Healthcare Conference
WINSTON-SALEM, N.C., June 01, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kid...
ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights
WINSTON-SALEM, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidn...
ProKidney to Present at the BofA Securities Health Care Conference 2023
WINSTON-SALEM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD),...
ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights
WINSTON-SALEM, N.C., March 28, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic ki...
ProKidney to Participate in TD Cowen's 43rd Annual Health Care Conference
WINSTON-SALEM, N.C., March 03, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD...
ProKidney's stock jumps 29%
Shares of ProKidney Corp. PROK, +9.57% rallied about 29% in premarket trading on Wednesday, the day after the company said preliminary data from a Phase 2 study found that the company's investigationa...
ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease
- Article published online in the Journal of Blood Purification; to be included in future print edition -
ProKidney to Present at the J.P. Morgan 41st Annual Healthcare Conference
WINSTON-SALEM, N.C., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD)...
ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
WINSTON-SALEM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kid...
ProKidney to Participate in Upcoming Investor Conferences
WINSTON-SALEM, N.C., Nov. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD)...
ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease
WINSTON-SALEM, N.C., Nov. 03, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD)...
ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2022
- Company will present five posters discussing REACT and chronic kidney disease during the ASN Annual Meeting, November 3 - 6, 2022
ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit
WINSTON-SALEM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD...
ProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
WINSTON-SALEM, N.C., Sept. 08, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD...
ProKidney Appoints Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations
Brings nearly 20 years of investor relations and corporate communications experience to ProKidney
ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Update
Completed business combination with Social Capital Suvretta Holdings, III Completed business combination with Social Capital Suvretta Holdings, III
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney
ProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs
Extensive Nephrology Medical Affairs Leadership and Clinical Practice Expertise Brought to ProKidney Extensive Nephrology Medical Affairs Leadership and Clinical Practice Expertise Brought to ProKidne...